Aclaris terminates CMO, enters separation with former CEO; promotes CSO to full-time

Aclaris Therapeutics, Inc.

Terminated Gail Cawkwell as CMO effective Jan 31, 2024, without cause; receives 12-month salary continuation and COBRA coverage.
Entered separation agreement with former CEO Douglas Manion on Feb 4, 2024; receives 12-month salary continuation plus unpaid 2023 bonus.
Amended CSO Joseph Monahan's employment; base salary raised to $430,000, moves from part-time to full-time effective Feb 1, 2024.
Monahan’s new agreement has a 2-year initial term with automatic one-year renewals unless 90-day notice is given.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Douglas Manion

Chief Executive Officer and President

ACRS · Aclaris Therapeutics, Inc.

Filed: February 5, 2024, 6:59 PM ET

On February 4, 2024, in connection with Douglas Manion’s departure from the Company as the Company’s Chief Executive Officer and President, the Company and Dr. Manion entered into a Separation Agreement

Departed

Gail Cawkwell

Chief Medical Officer

ACRS · Aclaris Therapeutics, Inc.

Effective: 2024-01-31
Filed: February 5, 2024, 6:59 PM ET

On January 31, 2024, Aclaris Therapeutics, Inc. (the “ Company ”) terminated the employment of Gail Cawkwell, M.D., PhD., the Company's Chief Medical Officer, without cause, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Douglas Manion departed as Chief Executive Officer and President at Aclaris Therapeutics, Inc..

Action: departed
Role: Chief Executive Officer and President

Exact text from the filing

On February 4, 2024, in connection with Douglas Manion’s departure from the Company as the Company’s Chief Executive Officer and President, the Company and Dr. Manion entered into a Separation Agreement

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gail Cawkwell was terminated as Chief Medical Officer at Aclaris Therapeutics, Inc..

Action: terminated
Role: Chief Medical Officer

Exact text from the filing

On January 31, 2024, Aclaris Therapeutics, Inc. (the “ Company ”) terminated the employment of Gail Cawkwell, M.D., PhD., the Company's Chief Medical Officer, without cause, effective immediately.

View on SEC.gov

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-000769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.